University of Minnesota. Driven to Discover.
With resistance emerging to a limited set of treatment options, new drugs for invasive fungal infections are desperately needed.
About a quarter of the 200 colonized patients had clinical illness, including 27 with bloodstream infections.
If illness from the fungus becomes more common, "We are dealing with the potential for a highly resistant bug to really take off."
Get CIDRAP news and other free newsletters.
Sign up now»
Unrestricted financial support provided by
Grant support for ASP provided by
CIDRAP - Center for Infectious Disease Research and PolicyOffice of the Vice President for Research, University of Minnesota, Minneapolis, MN
© 2019 Regents of the University of Minnesota. All rights reserved.The University of Minnesota is an equal opportunity educator and employer.